Abstracts tagged "autoimmune diseases"

Abstract Number: 1985 • ACR Convergence 2022
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
Thomas Jonassen¹, Irene Sandholdt², Birgitte Telmer² and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammatory activity and the promotion of inflammatory resolution. AP1189 is novel biased…
Abstract Number: 2237 • ACR Convergence 2022
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Rohit Aggarwal¹, Ingrid Lundberg², Yeong-Wook Song³, Aziz Shaibani⁴, Victoria Werth⁵ and Michael Maldonado⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Seoul National University, Seoul, Republic of Korea, ⁴Nerve and Muscle Center of Texas, Houston, TX, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
Abstract Number: 0084 • ACR Convergence 2022
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
Silke Neusser¹, Anja Neumann¹, Christian Speckemeier¹, Pauline zur NIeden¹, Sarah Schlierenkamp¹, Anke Walendzik¹, Ute Karbach², Ioana Andreica³, Kristina Vaupel⁴, Xenofon Baraliakos⁵ and Uta Kiltz⁴, ¹Essener Forschungsinstitut für Medizinmanagement, Essen, Germany, ²Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Cologne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study…
Abstract Number: 0209 • ACR Convergence 2022
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Thomas Vazquez⁶, Felix Chin⁷, Barbara White⁸ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶FIU Wertheim College of Medicine, Virginia Beach, VA, ⁷University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁸SFJ Pharmaceuticals, Towson, MD
Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…
Abstract Number: 0581 • ACR Convergence 2022
Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders
Yingying Hu¹, Hu Ge¹, Yuxi Yan¹, Yun Zhang², Xiaoxing Huang¹, Zhenna Gao², Yiming Kou², Mi Ye², Lei Zhou¹, Siyuan Shao¹, Bowei Yin¹, Zhenzhen Li¹, Yayuan Fu¹, Wenqing Yang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Low-dose IL-2 with enhanced sensitivity to Treg cells has been proved to be safe and efficacious in multiple autoimmune disorders (AIDs) including SLE, RA,…
Abstract Number: 0671 • ACR Convergence 2022
Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Rebecca K.Leaf², Danieli Castro Oliveira de Andrade³, Megan Barber⁴, Maria G. Tektonidou⁵, Vittorio Pengo⁶, Savino Sciascia⁷, Amaia Ugarte⁸, H Michael Belmont⁹, Chary López-Pedrera¹⁰, Paul R Fortin¹¹, maria gerosa¹², Guilherme de Jesús¹³, Tatsuya Atsumi¹⁴, ZHUOLI ZHANG¹⁵, Hannah Cohen¹⁶, D. Ware Branch¹⁷, Denis WAHL¹⁸, Laura Andreoli¹⁹, Esther Rodriguez Almaraz²⁰, Michelle Petri²¹, Ricard Cervera²², Yu (Ray) Zuo²³, Bahar Artim-Esen²⁴, ²⁵, Rohan Willis²⁶, Maria Laura Bertolaccini²⁷, Robert Roubey²⁸, Doruk Erkan¹ and on behalf of APS ACTION On Behalf Of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Boston, MA, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Torino, Italy, ⁸BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹²University of Milan, Milano, Italy, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴Hokkaido University, Sapporo, Japan, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁷University of Utah, Salt Lake City, UT, ¹⁸University of Lorraine, Nancy, France, ¹⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²²Hospital Clinic Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²⁶University of Texas Medical Branch, Galveston, TX, ²⁷King's College London, London, United Kingdom, ²⁸University of North Carolina, Chapel Hill, NC
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
Abstract Number: 0757 • ACR Convergence 2022
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
Pankti Reid¹, Sabina Sandigursky², Maria A. Lopez-Olivo³, Juhee Song⁴, Houssein Safa⁵, Samuel Cytryn⁶, Maryam Buni⁷, Anna Pavlick⁸, Michelle Krogsgaard, PhD⁹, Osama Abu-Shawer¹⁰, Mehmet Altan¹¹, Jeffrey Weber¹², Maria Suarez-Almazor¹³, Adi Diab¹⁴ and Noha Abdel-Wahab¹⁴, ¹University of Chicago Medical Center, Chicago, IL, ²NYU Langone Health, New York, NY, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁶Memorial Sloan Kettering Cancer Center, New York, NY, ⁷MD Anderson Cancer Center, Bellaire, TX, ⁸Medical Oncology, Weill Cornell Medical Center, New York, NY, ⁹Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, ¹⁰Cleveland Clinic Foundation, Cleveland, OH, ¹¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ¹²NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, ¹³MD Anderson Cancer Center, Houston, TX, ¹⁴UT MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…
Abstract Number: 0810 • ACR Convergence 2022
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
María Paula Álvarez Hernández¹, Alejandro Gómez Gómez², Lara Borrego Sanz³, Rosalía Méndez Fernández³, Pedro Arriola Villalobos³, Esperanza Pato Cour⁴, David Díaz Valle³ and Luis Rodriguez-Rodriguez⁴, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct…
Abstract Number: 1051 • ACR Convergence 2022
A Deep Neural Network Classifier to Identify Intrinsic Molecular Subsets of Systemic Sclerosis Using Histological Images
Yiwei Yuan¹, Qingyuan Song¹, Paul Harms², Johann Gudjonsson², Robert Lafyatis³, Dinesh Khanna⁴ and Michael Whitfield⁵, ¹Dartmouth College, Lebanon, NH, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁵Geisel School of Medicine, Lebanon, NH
Background/Purpose: Intrinsic gene analyses based on the gene expression profiles in skin have identified four intrinsic molecular subsets among patients with systemic sclerosis (SSc); these…
Abstract Number: 1220 • ACR Convergence 2022
Autonomic Dysfunction in Sjogren’s Disease
Ardy Fenando¹, Jordan Estes¹, Maha Mohamad¹, Sareena Shah², John Lee², Duaa Jabari¹, Joshua Baker³ and Ghaith Noaiseh¹, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Missouri-Kansas City, Kansas City, MO, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Sjogren's Disease (SjD) is a heterogenous autoimmune disease associated with debilitating symptoms. Autonomic dysfunction (AD) is common in SjD and may contribute to symptom…
Abstract Number: 1480 • ACR Convergence 2022
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Clarice P. Lin¹ and Richard C. Chou², ¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, ²University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY
Background/Purpose: Kidney disease is a common manifestation of systemic lupus erythematosus (SLE); when it presents as glomerulonephritis also known as lupus nephritis (LN), it predicts…
Abstract Number: 1708 • ACR Convergence 2022
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
Bahtiyar Toz¹, Jeffrey C wingard², Bruce Volpe² and Betty Diamond², ¹Resident in Queens Hospital Center, Jamaica, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Neurologic dysfunction occurs in up to 80% of SLE patients. Cognitive impairment is one of the most frequent manifestations of neuropsychiatric SLE (NPSLE). There…
Abstract Number: 1990 • ACR Convergence 2022
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
Abstract Number: 2247 • ACR Convergence 2022
Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions
Shilpa Venkatachalam¹, William Benjamin Nowell², Shubhasree Banerjee³, Kelly Gavigan⁴, Laura Stradford², Jennifer Gordon⁵, Lisa Emerich⁶, Hope Sullivan⁷, Ashira Blazer⁸, Brittany Banbury⁹, Vandana Dronadula¹, Kimberly Weaver¹⁰, Angela Degrassi⁴, Peter Merkel³, Robert McBurney¹¹, Mike Kappelman¹⁰, Jeffrey Curtis¹² and Michael George³, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Vasculitis Foundation, Philadelphia, ⁶iConquerMS, Waltham, MA, ⁷Inflammatory Bowel Disease (IBD) Partners, Chapel Hill, NC, ⁸Hospital for Special Surgery, New York, NY, ⁹NYU Langone, Fort Lee, NJ, ¹⁰School of Medicine, University of North Carolina (UNC), Chapel Hill, NC, ¹¹Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Compared to the general population, adults living with autoimmune disease are at nearly twice the risk of vaccine-preventable infections, making this a high priority…
Abstract Number: 0120 • ACR Convergence 2022
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Carla J. Guthridge¹, Catriona Wagner², Sohail Khan³, Michael Peercy⁴, Bobby Saunkeah⁴, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Cherokee Nation, Tahlequah, OK, ⁴Chickasaw Nation, Ada, OK
Background/Purpose: EBV infection is associated with autoantibody development in the preclinical period of rheumatic diseases, such as SLE and RA. Furthermore, EBV reactivation, characterized by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].